Preeti Kishore Bajpai

Prof. Preeti Kishore Bajpai


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
FFFaria Fatima
Faria Fatima
SVSmita Rastogi Verma
Smita Rastogi Verma
NPNeelam Pathak
Neelam Pathak
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai

9 August 2022 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
RSRafia Shekh
Rafia Shekh
Rohit Kumar Kumar TiwariRohit Kumar Kumar Tiwari
Rohit Kumar Kumar Tiwari
AAAfza Ahmad
Afza Ahmad
IAIrfan Ahmad
Irfan Ahmad
NANadiyah M. Alabdallah
Nadiyah M. Alabdallah
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai

19 April 2020 in International Journal of Neuroscience
Verified
Journal Article
Closed access
Rohit Kumar Kumar TiwariRohit Kumar Kumar Tiwari
Rohit Kumar Kumar Tiwari
SSSarika Singh
Sarika Singh
CGChhedi Lal Gupta
Chhedi Lal Gupta
PPPratibha Pandey
Pratibha Pandey
VSVipendra Kumar Singh
Vipendra Kumar Singh
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai
Glioblastoma multiforme (GBM) is the most severe forms of brain cancer, eventually becoming the leading cause of brain cancer-related death worldwide. Owing to the bleak surgical interventions and resistance to the different treatment regime, glioblastoma multiforme is a parlous disease demanding newer therapeutical perspective for its treatment. Toll-like Receptors (TLRs) are well-known members of Pathogen Recognition Receptors (PRRs) and have been extensively explored for their therapeutic and prophylactic potential in an array of disease including cancer. Recent trends in drug delivery research has shown shift towards delivering short DNA sequences (CpG DNA) to endosomal TLR9 within immune cells (macrophages, dendritic cells, etc.) for activation of desired inflammatory response using non-agonistic β-glucan particles; a well-known ligand for Dectin-1 receptors. Our study explores the role of nano-encapsulated CpG ODN as critical players in polarizing M2 scavenging to much desired pro-inflammatory type. The constructed Schizophyllan (SPG) nanoparticles entrapping CpG ODN 1826 (95.3%) were of 25.49 nm in diameter and thus capable of crossing blood-brain barrier. The rat glioblastoma (C6) cells were evaluated for intracellular oxidative burst and cytokine levels pre and post incubation with CpG ODN and nanoparticles. The cells prior to treatment exhibited high levels of IL-4 and low levels of IFN-γ and IL-1β. However, post treatment results revealed significantly high expression of intracellular ROS and IFN-γ as well as IL-1β. These alterations indicated towards the repolarization of macrophages from M2 to M1phase.

21 January 2019 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CGChhedi Lal Gupta
Chhedi Lal Gupta
MKMohd. Babu Khan
Mohd. Babu Khan
DADinakara Rao Ampasala
Dinakara Rao Ampasala
SASalman Akhtar
Salman Akhtar
UDUpendra Nath Dwivedi
Upendra Nath Dwivedi
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai
Toll-like receptor 7 (TLR7) is a transmembrane glycoprotein playing very crucial role in the signaling pathways involved in innate immunity and has been demonstrated to be useful in fighting against infectious disease by recognizing viral ssRNA & specific small molecule agonists. In order to find novel human TLR7 (hTLR7) modulators, computational ligand-based pharmacophore modeling approach was used to identify the molecular chemical features required for the modulation of hTLR7 protein. A training set of 20 TLR7 agonists with their known experimental activity was used to create pharmacophore model using 3D-QSAR pharmacophore generation (HypoGen algorithm) module in Discovery Studio. The best developed hypothesis consists of four pharmacophoric features namely, one hydrogen bond donor (HBD), one ring aromatic (RA), and two hydrophobic (HY) character. The developed hypothesis was then validated by different methods such as cost analysis, test set method, and Fischer’s test method for consistency. Hence, this validated model was further employed for screening of natural hit compounds from InterBioScreen Natural product database, consisting of more than 60,000 natural compounds and derivatives. The screened hit compounds were subsequently filtered by Lipinski’s rule of 5, ADME and toxicity parameters and molecular docking studies to remove the false positive rates. Finally, molecular docking analysis led to identification of the (3a′S,6a′R)-3′-(3,4-dihydroxybenzyl)-5′-(3,4-dimethoxyphenethyl)-5-ethyl-3′,3a′-dihydro-2′H-spiro[indoline-3,1′-pyrrolo[3,4-c]pyrrole]-2,4′,6′(5′H,6a′H)-trione (Compound ID: STOCK1N-65837) as potent hTLR7 modulator due to its better docking score and molecular interactions compared to other compounds. The result of virtual screening was further validated using molecular dynamics (MD) simulation analysis. Thus, a 30 ns MD simulation analysis revealed high stability and effective binding of STOCK1N-65837 within the binding site of hTLR7. Therefore, the present study provides confidence for the utility of the selected chemical feature based pharmacophore model to design novel TLR7 modulators with desired biological activity.

20 May 2011 in Journal of Parasitic Diseases
Verified
Journal Article
Closed access
PDF file
NSNishi Shakya
Nishi Shakya
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai
SGSuman Gupta
Suman Gupta

1 April 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CGChhedi Lal Gupta
Chhedi Lal Gupta
SASalman Akhtar
Salman Akhtar
AWAndrew Waye
Andrew Waye
NPNihar R. Pandey
Nihar R. Pandey
NPNeelam Pathak
Neelam Pathak
PBPreeti Kishore Bajpai
Preeti Kishore Bajpai